ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 276

Gender Differences in TNFi Treatment Adherence and Response in As Patients: A Prospective Longitudinal Cohort Study

S. Hoekstra1, Tamara Rusman2, Michael T. Nurmohamed3, Christiaan van Denderen4 and Irene van der Horst-Bruinsma5, 1Rheumatology, VU Univeresity Medical Center, Amsterdam, Netherlands, 2Rheumatology, VU University medical centre, Amsterdam, Netherlands, 3Rheumatology, Amsterdam Rheumatology and immunology Center, VU University Medical Center, Amsterdam, Netherlands, 4Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 5Rheumatology, VU University Medical Center, Amsterdam, Netherlands

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), Spondylarthritis and tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Healthcare Disparities in Rheumatology Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Despite several observations of gender differences in TNF inhibitor (TNFi) treatment response and adherence in ankylosing spondylitis (AS) patients, limited studies were conducted. Our aim is to assess gender differences in TNFi treatment adherence and response in a longitudinal cohort study over a 10-year follow-up period in AS patients.

Methods: AS patients (fulfilling the modified New York Criteria) treated consecutively with TNFi were included in a prospective, observational cohort. Data were collected at baseline, screening, 3 and 6 months and thereafter every 6 months on demographics, lifestyle factors, inflammatory markers (C-reactive Protein (CRP)) and disease specific parameters (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Metrology Index (BASMI)). TNFi response was defined by BASDAI50% response criteria (50% of the initial score or improvement of >2 points) and ASDAS response criteria (improvement of >1.1 points). Kaplan Meier Survival curves and Generalized Estimating Equations (GEE)-analyses were performed.

Results: In total 359 AS patients (33.4% females) were included with a mean follow-up of 5.1 years. Women showed a significant lower follow-up duration than men, 4.5 vs. 5.4 years. Patients who were lost to follow-up, were mostly still treated. Overall, females showed significantly higher disease activity scores, BASDAI (0.57 points) (figure 1) and ASDAS (0.27 points), compared to males over the entire follow-up period. According to both the BASDAI and the ASDAS response criteria, females had an overall significantly lower percentage of responders compared with males. In the secondary outcomes, females showed only a clinically relevant lower BASMI (higher mobility) than males (0.23 points).

Conclusion: Female AS patients showed a significantly lower follow-up duration, a lower improvement and a lower clinical response to TNFi according to the BASDAI and ASDAS response criteria.


Disclosure: S. Hoekstra, None; T. Rusman, None; M. T. Nurmohamed, AbbVie Inc., 2, 5,Pfizer, Inc., 2, 5,Merck & Co., 2, 5,Roche, 2, 5,BMS, 2, 5,UCB, Inc., 2, 5,Eli Lilly and Co., 2, 5,Celgene Corporation, 2, 5,Janssen, 2, 5; C. van Denderen, None; I. van der Horst-Bruinsma, AbbVie Inc., 2, 5,Pfizer, Inc., 2, 5,MSD, 2, 5,UCB, Inc., 2, 5.

To cite this abstract in AMA style:

Hoekstra S, Rusman T, Nurmohamed MT, van Denderen C, van der Horst-Bruinsma I. Gender Differences in TNFi Treatment Adherence and Response in As Patients: A Prospective Longitudinal Cohort Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/gender-differences-in-tnfi-treatment-adherence-and-response-in-as-patients-a-prospective-longitudinal-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/gender-differences-in-tnfi-treatment-adherence-and-response-in-as-patients-a-prospective-longitudinal-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology